Literature DB >> 18264978

Therapeutic options for patients with metastatic gastrointestinal carcinoid.

Herbert Chen.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18264978     DOI: 10.1002/jso.20956

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


× No keyword cloud information.
  4 in total

1.  KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.

Authors:  Guojun Chen; Renata Jaskula-Sztul; April Harrison; Ajitha Dammalapati; Wenjin Xu; Yiqiang Cheng; Herbert Chen; Shaoqin Gong
Journal:  Biomaterials       Date:  2016-04-26       Impact factor: 12.479

2.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

3.  Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging.

Authors:  Guojun Chen; Renata Jaskula-Sztul; Corinne R Esquibel; Irene Lou; Qifeng Zheng; Ajitha Dammalapati; April Harrison; Kevin W Eliceiri; Weiping Tang; Herbert Chen; Shaoqin Gong
Journal:  Adv Funct Mater       Date:  2017-01-17       Impact factor: 18.808

4.  Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.

Authors:  Yingnan Si; Seulhee Kim; Jianfa Ou; Yun Lu; Patrick Ernst; Kai Chen; Jason Whitt; Angela M Carter; James M Markert; James A Bibb; Herbert Chen; Lufang Zhou; Renata Jaskula-Sztul; Xiaoguang Margaret Liu
Journal:  Cancer Gene Ther       Date:  2020-07-20       Impact factor: 5.987

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.